A forum for researchers, students and applicants in the field of cyclodextrin technology
Researchers from Türkiye developed GE11-functionalized curcumin/carboxymethyl-β-cyclodextrin (Cur/CM-βCD) supramolecular assemblies, using GE11 as an EGFR-targeting peptide, to enhance the therapeutic potential
A new chapter in targeted cancer therapy On July 14, 2026, the U.S. FDA approved REVTORPYK™ (gedatolisib), developed by Celcuity,
This review critically examines how cyclodextrins modulate regulated cell death pathways and the implications for immunometabolism and therapeutic translation. Increasing
In this work, an integrated biophysical and biological study is presented describing both the structural and biological features of the
Glioblastoma (GB) is the most common and aggressive malignant brain tumor, with a median survival of only 12–15 months despite
This study provides a comprehensive analysis of the structures and properties of zinc sulfide (ZnS) and dysprosium-doped ZnS nanoparticles (NPs)
Topotecan (TPT), a potent anticancer agent, suffers from rapid hydrolysis of its active lactone ring under physiological conditions, severely limiting
The comprehensive physicochemical characterization and cyclodextrin complexation of four tyrosine kinase inhibitors — erlotinib, gefitinib, vandetanib, and lapatinib — were
Injectable biopolymer-based hydrogels have emerged as a powerful class of biomaterials designed for minimally invasive therapeutic strategies in modern medicine.
This workshop is part of the NextNano4Cancer project, funded under the ERA4Health Joint Transnational Call “Nano and advanced technologies for
